Serum HER-2/neu conversion to positive at the time of cancer progression in metastatic breast patients treated with letrozole vs. tamoxifen.

被引：0
|
作者：
Lipton, A
Leitzel, K
Ali, SM
Demers, L
Harvey, HA
Chaudri-Ross, HA
Lang, R
Hackl, W
Hamer, P
Carney, W
机构：
[1] Penn State Hershey Med Ctr, Lebanon VA Med Ctr, Hershey, PA USA
[2] Novartis Pharma AG, Basel, Switzerland
[3] Oncogene Sci Bayer Diagnost, Cambridge, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2003年 / 21卷 / 23期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：288S / 288S
页数：1
相关论文
共 50 条
  • [1] Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen.
    Lipton, A
    Mouridsen, H
    Ali, S
    Leitzel, K
    Demers, L
    Harvey, H
    Chaudri-Ross, HA
    Brady, C
    Dugan, M
    Carney, W
    BREAST CANCER RESEARCH AND TREATMENT, 2001, 69 (03) : 210 - 210
  • [2] Serum TIMP-1 and HER-2/neu levels in metastatic breast cancer (MBC) treated with either letrozole or tamoxifen
    Hamer, P. J.
    Lipton, A.
    Leitzel, K.
    Demers, L.
    Ali, S. M.
    Evans, D. B.
    Chaudri-Ross, H. A.
    Brown-Shimer, S.
    Pierce, K.
    Carney, W. P.
    Gaur, V.
    CLINICAL CHEMISTRY, 2009, 55 (06) : A156 - A156
  • [3] TRASTUZUMAB BEYOND PROGRESSION IN PATIENTS WITH HER-2/NEU POSITIVE METASTATIC BREAST CANCER
    Eralp, Yesim
    JOURNAL OF BREAST HEALTH, 2009, 5 (01): : 3 - 8
  • [4] Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy
    Lipton, A
    Leitzel, K
    Ali, SM
    Demers, L
    Harvey, HA
    Chaudri-Ross, HA
    Evans, D
    Lang, R
    Hackl, W
    Hamer, P
    Carney, W
    CANCER, 2005, 104 (02) : 257 - 263
  • [5] Serum HER-2/neu levels correlate with time to progression in therapy of metastatic breast cancer.
    Schippinger, W
    Bauernhofer, T
    Ploner, F
    Hofmann, G
    Krippl, P
    Neumann, R
    Wernecke, KD
    Samonigg, H
    BREAST CANCER RESEARCH AND TREATMENT, 2002, 76 : S104 - S104
  • [6] Superiority of letrozole over tamoxifen in the first-line treatment of metastatic breast cancer patients with normal serum HER-2/neu levels:: question of tamoxifen resistance
    Altundag, K
    Altundag, O
    JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (24) : 4656 - 4656
  • [7] Superiority of letrozole over tamoxifen in the first-line treatment of metastatic breast cancer patients with normal serum HER-2/neu levels:: question of tamoxifen resistance -: In Reply
    Lipton, A
    Leitzel, K
    Demers, L
    Harvey, HA
    Ali, SM
    Chaudri-Ross, HA
    Wyld, P
    Brady, C
    Carney, W
    JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (24) : 4657 - 4657
  • [8] Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen
    Lipton, A
    Ali, SM
    Leitzel, K
    Demers, L
    Harvey, HA
    Chaudri-Ross, HA
    Brady, C
    Wyld, P
    Carney, W
    JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (10) : 1967 - 1972
  • [9] Serum HER-2/neu levels in clinical studies with lapatinib in HER-2/neu positive breast cancer
    Maltzman, J.
    Blackwell, K.
    Stein, S.
    Martin, A.
    Westland, R.
    Burstein, H.
    Gomez, H.
    Gartner, N.
    Platek, G.
    Newmiller, M.
    Lipton, A.
    Carney, W. P.
    CLINICAL CHEMISTRY, 2008, 54 (06) : A130 - A130
  • [10] Study of serum EGFR, HER-2/neu, VEGF in metastatic breast cancer patients treated with taxanes.
    Labropoulos, SV
    Fountzilas, G
    Papadopoulos, S
    Karina, M
    Xylouri, M
    Doudoulakakis, A
    Chalkidou, S
    Razis, ED
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 66S - 66S
12345